Nanotechnology for chemothera0py drug capture
AssigneesThe Regents of the University of California, The Penn State Research Foundation
InventorsAmir Sheikhi, Alireza Khademhosseini
Life of this patent
Estimating the term…
Loading patent…
AssigneesThe Regents of the University of California, The Penn State Research Foundation
InventorsAmir Sheikhi, Alireza Khademhosseini
Estimating the term…
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
A composition of matter comprising electrosterically stabilized nanocrystalline cellulose, wherein the electrosterically stabilized nanocrystalline cellulose binds at least 1000 mg of doxorubicin per gram of electrosterically stabilized nanocrystalline cellulose when the electrosterically stabilized nanocrystalline cellulose is contacted with a fluid comprising doxorubicin.
Dependencies are inferred from the claim text.